NaNotics to Collaborate with Mayo Clinic on Nanomedicine Cancer Treatment

Jan. 4, 2022 18:00 UTC

MILL VALLEY, Calif.--(BUSINESS WIRE)-- NaNotics LLC, a nanomedical company focused on developing and commercializing NaNots™, a novel subtractive nanoparticle that treats disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration with Mayo Clinic to develop a NaNot that targets the soluble form of PD-L1, a tumor-generated immune inhibitor. The goal is to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) and commence human trials within two years.

This press release features multimedia. View the full release here:

NaNot Structure (Graphic: Business Wire)

NaNot Structure (Graphic: Business Wire)

Cancer cells with high levels of PD-L1 are able to “trick” the immune system into not attacking, allowing tumors to become more advanced. Approved drugs against PD-L1 do exist today but are limited in their capabilities. Specifically, they are unable to distinguish pathogenic soluble PD-L1 from membrane PD-L1 – which also has a vital immune regulatory role – leading to dose-limiting toxicity. Soluble PD-L1 – also known as “sPD-L1” – is elevated in many cancer patients and correlates very negatively with survival.

NaNots are distinct from drug therapies in that they deplete soluble targets without engaging membrane forms of the same target, something that drugs generally cannot do. Furthermore, NaNots offer ultra-low toxicity in comparison to drug therapies. Multiple animal studies to date have shown no measurable NaNot toxicity – even at 25-100 times the planned dose in humans.

Sean Park, MD, PhD, oncologist at Mayo Clinic, stated, “Our team has been studying sPD-L1 for several years. We believe it’s a key driver of immune evasion for many tumor types. The ability to deplete sPD-L1 without incurring the toxicity of drugs against PD-L1 is potentially significant. We’re excited to collaborate with NaNotics and test NaNots against sPD-L1 in humans for the first time.”

“Collaborating with Dr. Park and his team at Mayo Clinic is a dream come true for us. Not only are they world-class scientists with extensive human trial experience, but they also possess deep knowledge of sPD-L1 specifically,” said Lou Hawthorne, CEO of NaNotics and the inventor of NaNots – the subject of 12 granted patents to date. “Dr. Park’s team includes Haidong Dong, MD, PhD, co-discoverer of PD-L1. All they need is a way to deplete the target, which we’re happy to provide with our platform. Together, we have an opportunity to explore a fundamentally new kind of treatment that could contribute to improved outcomes for millions of cancer patients.”

As part of the collaboration, NaNotics will provide its core nano-depletion platform and Mayo Clinic will provide an antibody of its own design against PD-L1, which will be specific to sPD-L1 once incorporated into a NaNot. Mayo Clinic will also provide a transgenic mouse model that secretes human sPD-L1, as well as a broad range of know-how.

Mayo Clinic and Drs. Sean Park and Haidong Dong have a financial interest in NaNots™ targeting sPD-L1. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About NaNotics LLC

NaNotics LLC is a mature preclinical stage company based in Mill Valley, CA, just north of San Francisco. The company has 12 granted patents on its NaNot™ nano-depletion platform – half in the U.S. and half in key foreign countries – with many more patents pending. The company is developing a pipeline of eight NaNots™ against a range of inflammatory and inhibitory targets driving multiple diseases representing significant unmet medical need. To learn more, visit us at or follow us on LinkedIn.


Media Contacts
Meghan Witthaus
(415) 800-5389
10Fold Communications

Song Schreiber, MS, MBA
NaNotics LLC
(408) 656-4689


Source: NaNotics LLC

Smart Multimedia Gallery

NaNot Structure (Graphic: Business Wire)

View this news release and multimedia online at:

Back to news